FLOW · 2024

FLOW — Semaglutide kidney outcomes in T2D

Semaglutide and progression of kidney disease in T2D.

Headline finding

24% reduction in composite of major kidney disease events.

Population
3,533 adults with T2D and CKD
Duration
156 weeks
Citation
Perkovic V et al., NEJM 2024

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation